MADSION, Wis.--(BUSINESS WIRE)--Ocular Services on Demand LLC (OSOD), a consortium of experts in vision science working to accelerate the identification and development of new ophthalmic therapies and devices, today announced the availability of an engaging new 16 hour continuing education series that focuses on the basic science that underlies ocular drug and device development. Topics covered include comparative ocular functional morphology, ocular physiology and pharmacology, ocular immunology, electrodiagnostics, clinical assessment and use of scoring systems, advanced imaging techniques and ocular pathology.
The series can be delivered en toto or by selected topics at the company’s site and/or by webinar during a timeframe that works best for a given company. Pharmaceutical and biotech companies that are developing ophthalmic drugs or devices will derive the most benefit from the series. The development of ocular therapeutics presents a number of complex scientific challenges because of the eye’s unique anatomy and physiology. The series can be tailored to the specific needs of any company based on its unique ocular drug development challenges. Some of the leading experts in the field are available for specific discussion focused on overcoming challenges encountered in specific drug/device development programs.
“OSOD is delighted to offer this important continuing education series on ocular drug development,” said Christopher J. Murphy, DVM, PhD, DACVO, CEO of Ocular Services on Demand. “The combination of important, salient topics and expert, stimulating speakers makes this series beneficial to companies engaged in ocular drug and device development. According to the feedback we’ve received, the detailed coverage of topics ensures that development teams possess a common fundamental knowledge and are familiar with the unique terminology employed in the execution and analysis of ocular studies.”
The entire series was initially delivered by invitation to the U.S. Food and Drug Administration and has subsequently been presented to a number of companies firmly committed to ocular drug development including Genentech Inc.